​

MBX Biosciences (MBX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MBX Stock Forecast

MBX Biosciences (MBX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $56.40, with a high of $88.00 and a low of $18.00. This represents a 39.92% increase from the last price of $40.31.

MBX Stock Rating

MBX Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

MBX Price Target Upside V Benchmarks

TypeNameUpside
StockMBX Biosciences39.92%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts156
Avg Price Target$66.00$56.40$53.33
Last Closing Price$40.31$40.31$40.31
Upside/Downside63.73%39.92%32.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2628-1-11
Jan, 2617-1-9
Dec, 2517---8
Nov, 2526---8
Oct, 2525---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026Barclays$66.00$36.0782.98%63.73%
Jan 16, 2026Seamus FernandezGuggenheim$88.00$40.91115.11%118.31%
Jan 07, 2026Michael YeeUBS$60.00$28.70109.06%48.85%
Dec 19, 2025Annabel SamimyStifel Nicolaus$50.00$28.6774.40%24.04%
Dec 04, 2025Goldman Sachs$18.00$33.94-46.97%-55.35%
Aug 05, 2025Mizuho Securities$38.00$11.95217.99%-5.73%
Oct 08, 2024Seamus FernandezGuggenheim$44.00$24.2081.82%9.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 27, 2026BarclaysOverweightinitialise
Jan 16, 2026GuggenheimBuyBuyhold
Jan 07, 2026UBSBuyinitialise
Dec 04, 2025Goldman SachsSellinitialise
Nov 04, 2025Cowen & Co.Buyinitialise
Sep 22, 2025CitigroupOutperformOutperformhold
Sep 22, 2025OppenheimerOutperformOutperformhold
Sep 22, 2025GuggenheimBuyBuyhold
Oct 08, 2024JefferiesBuyinitialise
Oct 08, 2024GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast$-11.52$-2.82$-2.76$-3.45$-2.95$-2.77
High Forecast$-5.28$-2.44$-2.25$-3.22$-2.95$-2.77
Low Forecast$-23.87$-3.11$-3.08$-3.69$-2.95$-2.77
Surprise %------

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast-----$44.05M
High Forecast-----$44.05M
Low Forecast-----$44.05M
Surprise %------

Net Income Forecast

$-800M $-650M $-500M $-350M $-200M $-50M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-61.92M-----
Avg Forecast$-486.68M$-102.04M$-89.01M$-115.46M$-98.51M$-92.50M
High Forecast$-176.21M$-81.59M$-75.30M$-107.56M$-98.51M$-92.50M
Low Forecast$-797.16M$-103.73M$-102.71M$-123.35M$-98.51M$-92.50M
Surprise %-87.28%-----

MBX Forecast FAQ

Is MBX Biosciences stock a buy?

MBX Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MBX Biosciences is a favorable investment for most analysts.

What is MBX Biosciences's price target?

MBX Biosciences's price target, set by 4 Wall Street analysts, averages $56.4 over the next 12 months. The price target range spans from $18 at the low end to $88 at the high end, suggesting a potential 39.92% change from the previous closing price of $40.31.

How does MBX Biosciences stock forecast compare to its benchmarks?

MBX Biosciences's stock forecast shows a 39.92% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MBX Biosciences over the past three months?

  • February 2026: 18.18% Strong Buy, 72.73% Buy, 0% Hold, 9.09% Sell, 0% Strong Sell.
  • January 2026: 11.11% Strong Buy, 77.78% Buy, 0% Hold, 11.11% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MBX Biosciences’s EPS forecast?

MBX Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.82, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-2.76 in 2026, $-3.45 in 2027, $-2.95 in 2028, and $-2.77 in 2029.

What is MBX Biosciences’s revenue forecast?

MBX Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, $0 for 2028, and $44.05M for 2029.

What is MBX Biosciences’s net income forecast?

MBX Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-102M, representing an 64.79% increase from the reported $-61.922M in 2024. Projections indicate $-89.007M in 2026, $-115M in 2027, $-98.508M in 2028, and $-92.498M in 2029.